Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Book value per share
Vertex Pharmaceuticals Incorporated's book value per share at the end of fiscal 2025 was 73.0×, up 14.7% from 63.6× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 79.8×. Over the past ten years it has ranged from 4.5× (fiscal 2015) to 73.0× (fiscal 2025) — the current reading is the highest in ten years. Vertex Pharmaceuticals Incorporated ranks 10th of 612 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 73.0× | 14.73% |
| FY2024 | 63.6× | (6.73%) |
| FY2023 | 68.2× | 25.58% |
| FY2022 | 54.3× | 38.61% |
| FY2021 | 39.2× | 17.22% |
| FY2020 | 33.4× | 41.05% |
| FY2019 | 23.7× | 35.92% |
| FY2018 | 17.4× | 112.53% |
| FY2017 | 8.2× | 50.06% |
| FY2016 | 5.5× | 20.68% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 79.8× | 4.74% |
| Mar 2026 | 76.2× | 4.38% |
| Dec 2025 | 73.0× | 7.74% |
| Sep 2025 | 67.8× | 1.27% |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | 308× |
| ARGX argenex SE compare | 135× |
| VRTX Vertex Pharmaceuticals Incorporated | 79.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 46.4× |
| RPRX Royalty Pharma PLC compare | 22.0× |
| MRNA Moderna, Inc. compare | 17.0× |
| RVMD Revolution Medicines, Inc. compare | 12.4× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 10.1× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement